Table 1 Estimated prevalence of SARS-CoV-2 neutralising antibodies in the French population from March-May 2020.

From: Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance

 

9–15 March 2020

6–12 April 2020

11–17 May 2020

 

P (%)

95% CI

P (%)

95% CI

P (%)

95% CI

Overall

0.1

0.0; 0.2

2.6

2.1; 3.2

3.3

2.7; 4.1

Sex

 Male

0.1

0.0; 0.2

2.9

2.2; 3.7

3.7

2.9; 4.7

 Female

0.1

0.0; 0.2

2.4

1.8; 3.0

3.0

2.3; 3.8

Age group, years

 0–9

0.0

0.0; 0.1

1.3

0.4; 2.4

1.6

0.5; 3.1

 10–19

0.1

0.0; 0.2

2.6

1.6; 3.9

3.3

2.1; 4.8

 20–29

0.1

0.0; 0.2

2.5

1.5; 3.7

3.2

1.9; 4.8

 30–39

0.0

0.0; 0.1

1.8

1.0; 2.8

2.3

1.3; 3.6

 40–49

0.1

0.0; 0.3

3.9

2.6; 5.4

4.9

3.4; 6.9

 50–59

0.1

0.0; 0.3

3.6

2.4; 4.9

4.5

3.1; 6.2

 60–69

0.1

0.0; 0.2

2.8

1.9; 4.0

3.6

2.4; 5.1

 70–79

0.1

0.0; 0.2

2.3

1.5; 3.4

3.0

1.9; 4.2

 ≥80

0.1

0.0; 0.2

2.5

1.6; 3.7

3.2

2.1; 4.5

Regions

 Guadeloupe

0.0

0.0; 0.1

1.3

0.5; 2.4

1.7

0.7; 3.1

 Martinique

0.0

0.0; 0.1

0.7

0.2; 1.4

0.9

0.3; 1.8

 French Guiana

0.1

0.0; 0.2

2.1

0.8; 4.3

2.7

1.0; 5.4

 La Reunion

0.0

0.0; 0.1

0.9

0.2; 2.2

1.2

0.3; 2.8

 Île-de-france

0.1

0.0; 0.4

5.7

4.3; 7.4

7.3

5.5; 9.4

 Centre-Val-de-Loire

0.0

0.0; 0.1

1.0

0.3; 2.3

1.3

0.4; 2.8

 Bourgogne-Franche Comté

0.1

0.0; 0.2

2.4

1.1; 4.2

3.0

1.4; 5.4

 Normandie

0.0

0.0; 0.1

1.5

0.7; 2.8

1.9

0.9; 3.5

 Hauts-de-France

0.0

0.0; 0.1

1.9

1.0; 3.1

2.4

1.3; 3.9

 Grand-Est

0.1

0.0; 0.4

5.6

3.5; 8.1

7.0

4.5; 10.1

 Pays de la Loire

0.0

0.0; 0.1

1.7

0.7; 3.2

2.2

0.9; 4.1

 Bretagne

0.0

0.0; 0.1

1.1

0.3; 2.4

1.4

0.4; 3.1

 Nouvelle-Aquitaine

0.0

0.0; 0.1

1.1

0.5; 2.0

1.4

0.7; 2.5

 Occitanie

0.0

0.0; 0.1

0.9

0.3; 1.8

1.2

0.4; 2.4

 Auvergne-Rhône-Alpes

0.1

0.0; 0.2

2.2

1.2; 3.6

2.8

1.5; 4.5

 Provence-Alpes-Côte d'Azur

0.0

0.0; 0.1

1.2

0.6; 2.0

1.5

0.7; 2.6

 Corse

0.0

0.0; 0.1

1.1

0.3; 2.7

1.4

0.4; 3.5